CR20160563A - Péptidos como agonistas de la oxitocina - Google Patents
Péptidos como agonistas de la oxitocinaInfo
- Publication number
- CR20160563A CR20160563A CR20160563A CR20160563A CR20160563A CR 20160563 A CR20160563 A CR 20160563A CR 20160563 A CR20160563 A CR 20160563A CR 20160563 A CR20160563 A CR 20160563A CR 20160563 A CR20160563 A CR 20160563A
- Authority
- CR
- Costa Rica
- Prior art keywords
- hydrogen
- lower alkyl
- cycloalkyl
- chr4
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a compuestos de fórmula en donde R1 es hidrógeno, alquilo inferior o cicloalquilo; R2 es hidrógeno o R1 y R2 pueden formar junto con el átomo de N y C al que están unidos un anillo de pirrolidina opcionalmente sustituido con uno o dos átomos de F o con hidroxi, o puede formar una azetidina o un anillo de piperazina; R3 es hidrógeno, alquilo inferior, alquilo inferior sustituido con hidroxi, -(CH2)2C(O)NH2, bencilo, fenilo, -CH2-grupo heterocíclico aromático de cinco miembros, CH2-indolilo, -CH2-cicloalquilo, cicloalquilo -(CH2)2-S-alquilo inferior; R3¿ es hidrógeno o alquilo inferior; o X es ¿C(O)-CHR4-CHR4¿-C(O)-NH-CH2- R4/R4¿ son hidrógeno o uno de R4 o R4¿ es amino: o es 0 o 1; o a una sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a sus enantiómeros y/o isómeros ópticos de los mismos. Se ha descubierto que los presentes compuestos son agonistas del receptor de oxitocina para el tratamiento del autismo, el estrés, incluyendo el trastorno de estrés postraumático, la ansiedad, incluyendo trastornos de ansiedad y la depresión, la esquizofrenia, trastornos psiquiátricos y la pérdida de memoria, la abstinencia del alcohol, adicción a las drogas y para el tratamiento del síndrome de Prader-Willi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14170992 | 2014-06-03 | ||
PCT/EP2015/062054 WO2015185467A1 (en) | 2014-06-03 | 2015-06-01 | Peptides as oxytocin agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20160563A true CR20160563A (es) | 2017-01-06 |
Family
ID=50842169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20160563A CR20160563A (es) | 2014-06-03 | 2015-06-01 | Péptidos como agonistas de la oxitocina |
Country Status (16)
Country | Link |
---|---|
US (1) | US9957298B2 (es) |
EP (1) | EP3151849B1 (es) |
JP (1) | JP6412170B2 (es) |
KR (1) | KR20170004013A (es) |
CN (1) | CN106414479B (es) |
AU (1) | AU2015270723A1 (es) |
CA (1) | CA2949173A1 (es) |
CL (1) | CL2016003095A1 (es) |
CR (1) | CR20160563A (es) |
EA (1) | EA030091B1 (es) |
IL (1) | IL248553A0 (es) |
MX (1) | MX2016015873A (es) |
PE (1) | PE20161559A1 (es) |
PH (1) | PH12016502232A1 (es) |
SG (1) | SG11201610073PA (es) |
WO (1) | WO2015185467A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016044131A1 (en) | 2014-09-19 | 2016-03-24 | Ferring B.V. | Method of treating prader-willi syndrome |
US11414459B2 (en) | 2017-09-28 | 2022-08-16 | Kinoxis Therapeutics Pty Ltd | Metabolite inspired selective oxytocin receptor agonists |
AU2019345313A1 (en) | 2018-09-20 | 2021-03-18 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
AU2019345166B2 (en) * | 2018-09-20 | 2021-09-02 | Levo Therapeutics, Inc. | Stable intranasal formulations of carbetocin |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9701162D0 (sv) * | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
KR20070022753A (ko) * | 2004-05-26 | 2007-02-27 | 화이자 인코포레이티드 | 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도 |
WO2008091555A2 (en) * | 2007-01-22 | 2008-07-31 | Gtx, Inc. | Nuclear receptor binding agents |
NZ587817A (en) * | 2008-03-31 | 2012-05-25 | Ferring Bv | Oxytocin analogues |
KR20110076944A (ko) * | 2008-09-23 | 2011-07-06 | 에프. 호프만-라 로슈 아게 | 도파민 d3 수용체의 조절제로서 유용한 이속사졸로〔4,5〕피리딘-3-일-피페라진 유도체 |
CA2760597C (en) * | 2009-05-05 | 2017-08-22 | F. Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
WO2011038451A1 (en) * | 2009-10-01 | 2011-04-07 | The University Of Sydney | Therapy and prevention of problem drinking |
CA2895150C (en) | 2012-12-21 | 2019-11-26 | F. Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
-
2015
- 2015-06-01 EA EA201692404A patent/EA030091B1/ru not_active IP Right Cessation
- 2015-06-01 WO PCT/EP2015/062054 patent/WO2015185467A1/en active Application Filing
- 2015-06-01 MX MX2016015873A patent/MX2016015873A/es unknown
- 2015-06-01 AU AU2015270723A patent/AU2015270723A1/en not_active Abandoned
- 2015-06-01 SG SG11201610073PA patent/SG11201610073PA/en unknown
- 2015-06-01 JP JP2016571027A patent/JP6412170B2/ja not_active Expired - Fee Related
- 2015-06-01 CN CN201580027370.7A patent/CN106414479B/zh not_active Expired - Fee Related
- 2015-06-01 CA CA2949173A patent/CA2949173A1/en not_active Abandoned
- 2015-06-01 PE PE2016002397A patent/PE20161559A1/es unknown
- 2015-06-01 KR KR1020167036060A patent/KR20170004013A/ko not_active Application Discontinuation
- 2015-06-01 CR CR20160563A patent/CR20160563A/es unknown
- 2015-06-01 EP EP15725359.2A patent/EP3151849B1/en not_active Not-in-force
-
2016
- 2016-10-27 IL IL248553A patent/IL248553A0/en unknown
- 2016-11-09 PH PH12016502232A patent/PH12016502232A1/en unknown
- 2016-12-01 CL CL2016003095A patent/CL2016003095A1/es unknown
- 2016-12-02 US US15/368,080 patent/US9957298B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20170004013A (ko) | 2017-01-10 |
SG11201610073PA (en) | 2016-12-29 |
CN106414479A (zh) | 2017-02-15 |
US20170081369A1 (en) | 2017-03-23 |
US9957298B2 (en) | 2018-05-01 |
JP2017518311A (ja) | 2017-07-06 |
CN106414479B (zh) | 2021-08-03 |
PH12016502232A1 (en) | 2017-01-09 |
IL248553A0 (en) | 2016-12-29 |
WO2015185467A1 (en) | 2015-12-10 |
EA201692404A1 (ru) | 2017-05-31 |
CA2949173A1 (en) | 2015-12-10 |
PE20161559A1 (es) | 2017-01-12 |
MX2016015873A (es) | 2017-03-27 |
EP3151849A1 (en) | 2017-04-12 |
CL2016003095A1 (es) | 2017-06-16 |
JP6412170B2 (ja) | 2018-10-24 |
AU2015270723A1 (en) | 2016-11-17 |
EP3151849B1 (en) | 2018-10-10 |
EA030091B1 (ru) | 2018-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094225A1 (es) | Peptidos como agonistas de oxitocina | |
EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
PH12016502231B1 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
CO2017011174A2 (es) | Derivados de etileno como moduladores metabotropicos de receptores de glutamato | |
CR20160563A (es) | Péptidos como agonistas de la oxitocina | |
AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
AR092555A1 (es) | 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc | |
PE20181853A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
AR097721A1 (es) | Derivados de etinilo | |
PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
AR106588A1 (es) | Derivados de indolin-2-ona para el tratamiento de enfermedades del snc | |
MX2015008830A (es) | Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central. | |
AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
CR20130476A (es) | Derivados de pirazolidin-3-ona | |
PE20161374A1 (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
AR107490A1 (es) | Derivados de pirazol-piridina como inhibidores de eaat3 | |
PE20171349A1 (es) | Inhibidores de bace1 | |
PE20150685A1 (es) | Pirimidinas de ariletinilo | |
UY36023A (es) | “derivados cristalinos de (s)-1-((2r,3r,4s,5s)-5-alil-3-metoxi-4-(tosilmetil) tetrahidrofuran-2-il)-3-aminopropan-2-ol “. | |
AR062950A1 (es) | Compuestos tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
TH167739A (th) | เปปไทด์เป็นตัวทำการออกซีโทซิน |